CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 40 enrolled
Drug / intervention
Dexlansoprazoledrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03316976
NCT03316976Phase 1Completed

A Phase 1, Single-Center, Open-Label, 2-Arm Parallel Group, Single-Dose Study to Evaluate the Pharmacokinetics of Dexlansoprazole 30 mg and 60 mg Delayed-Release Capsules in Healthy Chinese Subjects

Takeda·interventional·Posted Oct 23, 2017·Updated May 10, 2019

In Brief

A Phase 1 clinical trial evaluating Dexlansoprazole for Healthy Volunteers. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The purpose of this study is to assess the pharmacokinetics after a single dose of dexlansoprazole 30 and 60 mg delayed-release capsules in healthy Chinese participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--

Timeline

Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedOct 23, 2017
Enrollment StartNov 22, 2017
Primary CompletionFeb 8, 2018
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 8.7 years ago

Interventions

Dexlansoprazoledrug

Dexlansoprazole delayed-release capsule.